4QUIGLEY H A, BROMAN A T. The number of people with glaucoma worldwide in 2010 and 2020 [ J ]. Br J Ophthal- mol,2006,90 (3) 262 - 269.
5HEIJL A, BENGTSSON B. Long-term effects of timolol therapy in ocular hypertension: a double-masked, random- ised trial[ J ]. Graefes Arch Clin Exp Ophthalmo1,2000,238 (11) :877 -883.
6WEINREB R N, LEVIN L A. Is neuroprotection a viable therapy for glaucoma? [ J ]. Arch Ophthalmol, 1999,117 (11) : 1540 -1544.
7WEI Y, WANG N, LU Q, et al. Enhanced protein expres- sions of sortilin and p75NTR in retina of rat following ele- vated intraocular pressure-induced retinal isehemia [ J ]. Neurosei Lett,2007,429 (2/3) : 169 - 174.
8PERNET V, HAUSWIRTH W W, DI POLO A. Extracellular signal-regulated kinase 1/2 mediates survival, but not axon regeneration, of adult injured central nervous system neu- rons in vivo[ J]. J Neurochem,2005,93 (1) :72 -83.
9blUANG Y, CEN L P, LUO J M, et al. Differential roles of phosphatidyli-nositol 3-kinsase/akt pathway in retinal gan- glion cell survival in rats with or without acute ocular hy- pertention [ J ]. Neurosei ,2008,153 ( 1 ) :214 - 225.
10SINGHAL S, LAWRENCE JM, SALT TE, et al. Triamci- nolone attenuates macrophage/microglia accumulation as- sociated with NMDA-induced RGC death and facilitates survival of MUller stem cell grafts[J]. Exp Eye Res,2010, 90(2) :308 -315.
